featured
Gilteritinib Superior to Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
N. Engl. J. Med 2019 Oct 31;381(18)1728-1740, AE Perl, G Martinelli, JE Cortes, A Neubauer, E Berman, S Paolini, P Montesinos, MR Baer, RA Larson, C Ustun, F Fabbiano, HP Erba, A Di Stasi, R Stuart, R Olin, M Kasner, F Ciceri, WC Chou, N Podoltsev, C Recher, H Yokoyama, N Hosono, SS Yoon, JH Lee, T Pardee, AT Fathi, C Liu, N Hasabou, X Liu, E Bahceci, MJ LevisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.